Robert Simon, MD
Urology · Cliffside Park, NJNPI 1992901052
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.7%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Medtronic accounts for 76.1% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $40,631 and has fallen 98.5% since, to $621 in 2025. Among urology clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 298 payments — averaging $362.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$82K
- Axonics, Inc.$24K
- Sumitomo Pharma America, Inc.$343
- Boston Scientific$342
- Coloplast$188
- Bluewind Medical$123
- plus $1K from 28 others
Across 5 payments — averaging $1645.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$8K
What the payments were for
- Consulting fees$48,28245%
- Speaking & faculty fees$39,74537%
- Travel & lodging$13,28912%
- Food & beverage$6,5786%
- Education$1270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 148 | $82,237 |
| Axonics, Inc. | 61 | $23,548 |
| Sumitomo Pharma America, Inc. | 12 | $343 |
| Boston Scientific | 8 | $342 |
| Coloplast | 2 | $188 |
| Bluewind Medical | 4 | $123 |
| Johnson & Johnson | 2 | $119 |
| Astellas Pharma US Inc | 7 | $103 |
| Tolmar, Inc. | 6 | $102 |
| Travere Therapeutics, Inc. | 6 | $101 |
| Procept Biorobotics Corporation | 3 | $89 |
| Intuitive Surgical | 2 | $83 |
| Bard Access Systems, Inc. | 2 | $82 |
| Myriad Genetic Laboratories, Inc. | 4 | $80 |
| AbbVie | 4 | $53 |
| Amgen | 3 | $43 |
| Olympus America Inc. | 2 | $43 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $30 |
| Clarus Therapeutics Inc. | 2 | $30 |
| Urovant Sciences Inc | 2 | $30 |
| Pfizer | 2 | $26 |
| Myovant Sciences Inc. | 2 | $24 |
| Dentsply IH Inc. | 1 | $24 |
| Bayer | 1 | $20 |
| ABC Home Medical Supply, Inc. | 1 | $20 |
| C. R. Bard Foundation, Inc. | 1 | $18 |
| Urogen Pharma, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $17 |
| AstraZeneca | 1 | $15 |
| Tolmar Pharmaceuticals, Inc. | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
| Verity Pharmaceuticals Inc. | 1 | $12 |
| Aytu Biopharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$108,022 in reported general payments places this provider in the 95th percentile of 401 urology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 181 | $124,818 |
| GemtesaVibegron | 109 | $96,423 |
| Silodosin | 281 | $27,329 |
| JatenzoTestosterone Undecanoate | 21 | $21,302 |
| Tamsulosin Hcl | 459 | $6,572 |
| Estradiol | 56 | $4,048 |
| Tadalafil | 14 | $2,660 |
| Solifenacin Succinate | 63 | $2,336 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 92 | $2,233 |
| Methenamine Hippurate | 28 | $1,911 |
| Finasteride | 103 | $1,636 |
| Dutasteride | 37 | $1,218 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 54 | $1,146 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 173 | $920 |
| Oxybutynin Chloride ErOxybutynin Chloride | 28 | $614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $103 | $124,818181 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $343 | $96,423109 claims |
| Clarus Therapeutics Inc.Jatenzo | $30 | $21,30221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 401 urology providers in New Jersey.
Other urology in Cliffside Park
- Thomas ChunCliffside Park$11K
- Michael StifelmanHackensack$1.4M
- Gordon BrownCherry Hill$1.3M
- Thomas MuellerLinwood$1.1M
- David SussmanLinwood$802K
- Michael IngberDenville$530K
- Ravi MunverHackensack$529K
- Grannum SantBridgewater$487K
- Mutahar AhmedMaywood$414K
- Kevin GioiaRumson$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.